XML 21 R12.htm IDEA: XBRL DOCUMENT v3.24.3
Intangible Assets, Net
9 Months Ended
Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets, Net
4.
Intangible Assets, Net

At September 30, 2024, the Company’s intangible assets, net, consisted of the following (in thousands):

 

Useful
Life
(Years)

 

Gross
September 30,
2024

 

 

Accumulated
Amortization

 

 

Net
September 30,
2024

 

Indefinite lived assets:

 

 

 

 

 

 

 

 

 

 

 

Trademarks

 

N/A

 

$

2,150

 

 

$

 

 

$

2,150

 

Licenses

 

N/A

 

 

1,900

 

 

 

 

 

 

1,900

 

Amortized intangible assets:

 

 

 

 

 

 

 

 

 

 

 

Network relationships

 

11-21

 

 

156,779

 

 

 

(111,626

)

 

 

45,153

 

Management contracts

 

15

 

 

22,832

 

 

 

(17,647

)

 

 

5,185

 

Member relationships

 

7-14

 

 

71,577

 

 

 

(17,582

)

 

 

53,995

 

Patient management platform

 

5

 

 

2,060

 

 

 

(2,060

)

 

 

 

Tradename/trademarks

 

20

 

 

1,011

 

 

 

(345

)

 

 

666

 

Developed technology

 

6

 

 

107

 

 

 

(48

)

 

 

59

 

 

 

 

$

258,416

 

 

$

(149,308

)

 

$

109,108

 

 

At December 31, 2023, the Company’s intangible assets, net, consisted of the following (in thousands):

 

Useful
Life
(Years)

 

Gross
December 31,
2023

 

 

Accumulated
Amortization

 

 

Net
December 31,
2023

 

Indefinite lived assets:

 

 

 

 

 

 

 

 

 

 

 

Trademarks

 

N/A

 

$

2,150

 

 

$

 

 

$

2,150

 

Amortized intangible assets:

 

 

 

 

 

 

 

 

 

 

 

Network relationships

 

11-21

 

 

150,679

 

 

 

(104,859

)

 

 

45,820

 

Management contracts

 

15

 

 

22,832

 

 

 

(16,662

)

 

 

6,170

 

Member relationships

 

10-14

 

 

24,077

 

 

 

(7,345

)

 

 

16,732

 

Patient management platform

 

5

 

 

2,060

 

 

 

(2,060

)

 

 

 

Tradename/trademarks

 

20

 

 

1,011

 

 

 

(308

)

 

 

703

 

Developed technology

 

6

 

 

107

 

 

 

(34

)

 

 

73

 

 

 

 

$

202,916

 

 

$

(131,268

)

 

$

71,648

 

 

For the three months ended September 30, 2024 and 2023, the Company recognized amortization expenses of $6.7 million and $3.2 million, respectively, in depreciation and amortization on the accompanying condensed consolidated statements of income. For the nine months ended September 30, 2024 and 2023, the Company recognized amortization expenses of $18.0 million and $9.5 million, respectively, in depreciation and amortization on the accompanying condensed consolidated statements of income. The Company determined that there was no impairment of its finite-lived intangible or long-lived assets during the nine months ended September 30, 2024 and 2023.

Future amortization expense is estimated to be as follows for the following years ending December 31 (in thousands):

 

 

Amount

 

2024 (excluding the nine months ended September 30, 2024)

 

$

6,630

 

2025

 

 

22,856

 

2026

 

 

18,642

 

2027

 

 

15,170

 

2028

 

 

12,459

 

Thereafter

 

 

29,301

 

 

 

 

 

Total

 

$

105,058